Alterola Biotech, Inc.

Equities

ABTI

US02152V1035

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 07:00:00 30/05/2024 pm IST			5-day change	1st Jan Change
0.0199 ^USD	+503.03%		+503.03%	+452.78%

20/02	Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Alterola Biotech, Inc. Announces Executive Changes

December 09, 2020 at 03:49 am IST

Alterola Biotech, Inc. accepted the resignation of Larson Elmore as CEO and appointed Timothy Paul Rogers as CEO on December 2, 2020. Timothy Paul Rogers currently serves as CEO of Green Ocean Pharma, Green Ocean UK Limited, and Novagean International Limited.

Latest news about Alterola Biotech, Inc.

Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	21/02	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	21/11	CI
Alterola Biotech, Inc. Announces Executive Changes	17/23/17	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	16/23/16	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	11/23/11	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	10/23/10	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	15/23/15	CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22/22/22	CI
Alterola Biotech, Inc. Executive Changes	08/22/08	CI
Alterola Biotech, Inc. Appoints Terry Rafih as A Member of Board of Directors	08/22/08	CI
Bright Green Corporation completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl.	04/22/04	CI
Sector Update: Health Care Stocks Rebound Slightly in Late Trade, Pare Losses	31/22/31	MT
Sector Update: Health Care Stocks Dropping Tuesday Afternoon	30/22/30	MT
Bright Green Corporation has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl for $4 million.	30/22/30	CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	18/22/18	CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	11/22/11	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	10/22/10	CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	02/22/02	CI
Alterola Biotech, Inc. Announces Removal of Lalit Kumar Verma as A Director	10/21/10	CI
Alterola Biotech, Inc. completed the acquisition of the assets from C2 Wellness Corporation.	02/21/02	CI
Alterola Biotech, Inc. signed an agreement to acquire the assets from C2 Wellness Corporation for $6.4 million.	16/21/16	CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt	19/21/19	CI
Alterola Biotech : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Interim CFO	06/21/06	MT
Alterola Biotech, Inc. Announces Executive Changes	06/21/06	CI
Alterola Biotech, Inc. Announces Executive Changes	06/21/06	CI

Chart Alterola Biotech, Inc.

Duration

Period

More charts

Company Profile

Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALTEROLA BIOTECH, INC.	+452.78%	28.84M
VERTEX PHARMACEUTICALS INCORPORATED	+15.54%	121B
REGENERON PHARMACEUTICALS, INC.	+13.48%	107B
BIONTECH SE	-5.14%	24.82B
ARGENX SE	+1.69%	22.48B
GENMAB A/S	-10.09%	18.32B
WUXI APPTEC CO., LTD.	-40.52%	16.33B
BEIGENE, LTD.	-14.67%	15.31B
NEUROCRINE BIOSCIENCES, INC.	+3.04%	14.08B
SAREPTA THERAPEUTICS, INC.	+24.75%	11.74B

Bio Therapeutic Drugs